Search
urofollitropin (puregon, serono, organon, FSH-beta, Fertinex, Metrodin, Bravelle)
Tradenames: Bravelle
Indications:
1) induction of ovulation in patients with polycystic ovarian disease
2) stimulation of development of multiple oocytes
3) infertility in women with proven hypopituitarism or who have not responded to clomifene
4) superovulation treatment for assisted conception (such as in vitro fertilization)
5) Metrodin HP is also used in the treatment of hypogonadotrophic hypogonadism in men for the stimulation of spermatogenesis
Contraindications: pregnancy category X
Dosage:
Powder for injection: 75 IU of FSH (0.83 mg, 2 mL)
Adverse effects:
1) common (> 10%)
- ovarian enlargement, swelling at site of injection, pain
2) less common (1-10%)
- hyperstimulation syndrome, fever/chills, rash, abdominal pain, diarrhea, arterial thromboembolism, nausea/vomiting
Mechanism of action: FSH-beta
Related
menotropins (Pergonal, Repronex)
General
endocrine agent
follicle-stimulating hormone [FSH]-beta chain; follitropin beta chain (FSHB, Follistim)
Database Correlations
PUBCHEM cid=62819
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Drugs.com
http://www.drugs.com/mtm/urofollitropin.html